

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Roque Humberto Ferreyro et al.

Application No: 10/549,409

Filing Date: September 14, 2005

Entitled: HYDRAULIC DEVICE FOR THE
INJECTION OF BONE CEMENT
IN PERCUTANEOUS
VERTEBROPLASTY

Conf. No. 1699

Group Art Unit: 3733

Examiner: Jay R. Sigler

I hereby certify that this correspondence is being filed via EFS Web on the date shown below.

Dated: September 5, 2008

Signature:

(Ronald E. Cahill)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir/Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB08 and it is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark

Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56 (b). It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The amount of \$180.00 for filing fees is being charged by credit card via EFS Web, and the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 141449, under Order No. 101896-890.

Dated: September 5, 2008

Respectfully submitted,

By:


 Ronald E. Cahill
 Registration No. 38,403
 NUTTER MCLENNEN & FISH LLP
 World Trade Center West
 155 Seaport Boulevard
 Boston, Massachusetts 02210-2604
 (617) 439-2000
 (617) 310-9000 (Fax)
 Attorney for Applicant